176 related articles for article (PubMed ID: 17543159)
1. Vascular endothelial growth factor in patients with psoriatic arthritis.
Fink AM; Cauza E; Hassfeld W; Dunky A; Bayer PM; Jurecka W; Steiner A
Clin Exp Rheumatol; 2007; 25(2):305-8. PubMed ID: 17543159
[TBL] [Abstract][Full Text] [Related]
2. Serological markers in psoriatic arthritis: promising tools.
Ramonda R; Modesti V; Ortolan A; Scanu A; Bassi N; Oliviero F; Punzi L
Exp Biol Med (Maywood); 2013 Dec; 238(12):1431-6. PubMed ID: 24146263
[TBL] [Abstract][Full Text] [Related]
3. Serum level of receptor activator of nuclear factor kappa-B ligand in patients with psoriasis.
Amin TE; ElFar NN; Ghaly NR; Hekal MM; Hassan AM; Elsaadany HM
Int J Dermatol; 2016 May; 55(5):e227-33. PubMed ID: 26712216
[TBL] [Abstract][Full Text] [Related]
4. Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis.
Shahidi-Dadras M; Haghighatkhah HR; Abdollahimajd F; Younespour S; Partovi Kia M; Zargari O
Int J Dermatol; 2016 Jan; 55(1):52-9. PubMed ID: 26135969
[TBL] [Abstract][Full Text] [Related]
5. Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis.
Ablin JN; Goldstein Z; Aloush V; Matz H; Elkayam O; Caspi D; Swartzenberg S; George J; Wohl Y
Rheumatol Int; 2009 Jan; 29(3):257-62. PubMed ID: 18704428
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control.
Nofal A; Al-Makhzangy I; Attwa E; Nassar A; Abdalmoati A
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):803-6. PubMed ID: 19309427
[TBL] [Abstract][Full Text] [Related]
7. Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations.
Flisiak I; Zaniewski P; Rogalska-Taranta M; Chodynicka B
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):302-7. PubMed ID: 21418334
[TBL] [Abstract][Full Text] [Related]
8. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor.
Creamer D; Allen M; Jaggar R; Stevens R; Bicknell R; Barker J
Arch Dermatol; 2002 Jun; 138(6):791-6. PubMed ID: 12056961
[TBL] [Abstract][Full Text] [Related]
9. Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients.
Myśliwiec H; Baran A; Harasim-Symbor E; Choromańska B; Myśliwiec P; Milewska AJ; Chabowski A; Flisiak I
Arch Dermatol Res; 2017 Mar; 309(2):79-86. PubMed ID: 27988894
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of angiogenic cytokines in psoriatic arthritis and SAPHO syndrome.
Przepiera-Będzak H; Fischer K; Brzosko M
Pol Arch Med Wewn; 2013; 123(6):297-302. PubMed ID: 23711571
[TBL] [Abstract][Full Text] [Related]
11. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis.
Shimauchi T; Hirakawa S; Suzuki T; Yasuma A; Majima Y; Tatsuno K; Yagi H; Ito T; Tokura Y
J Dermatol; 2013 Oct; 40(10):805-12. PubMed ID: 23915382
[TBL] [Abstract][Full Text] [Related]
12. Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40.
Ataseven A; Kesli R
G Ital Dermatol Venereol; 2016 Jun; 151(3):244-50. PubMed ID: 25279492
[TBL] [Abstract][Full Text] [Related]
13. Plasma YKL-40: a potential biomarker for psoriatic arthritis?
Jensen P; Wiell C; Milting K; Poggenborg RP; Østergaard M; Johansen JS; Skov L
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):815-9. PubMed ID: 22621388
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor alpha (TNF-alpha)-converting enzyme (TACE) and soluble TNF-alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B.
Serwin AB; Sokolowska M; Chodynicka B
Photodermatol Photoimmunol Photomed; 2007 Aug; 23(4):130-4. PubMed ID: 17598866
[TBL] [Abstract][Full Text] [Related]
15. Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome.
Przepiera-Będzak H; Fischer K; Brzosko M
Mediators Inflamm; 2015; 2015():785705. PubMed ID: 26339141
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis.
Yalçin B; Tezel GG; Arda N; Erman M; Alli N
Anal Quant Cytol Histol; 2007 Dec; 29(6):358-64. PubMed ID: 18225391
[TBL] [Abstract][Full Text] [Related]
17. Cytokine profiles during infliximab monotherapy in psoriatic arthritis.
Mastroianni A; Minutilli E; Mussi A; Bordignon V; Trento E; D'Agosto G; Cordiali-Fei P; Berardesca E
Br J Dermatol; 2005 Sep; 153(3):531-6. PubMed ID: 16120138
[TBL] [Abstract][Full Text] [Related]
18. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy.
Andrys C; Borska L; Pohl D; Fiala Z; Hamakova K; Krejsek J
Arch Dermatol Res; 2007 Mar; 298(10):479-83. PubMed ID: 17221216
[TBL] [Abstract][Full Text] [Related]
19. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.
Young HS; Summers AM; Bhushan M; Brenchley PE; Griffiths CE
J Invest Dermatol; 2004 Jan; 122(1):209-15. PubMed ID: 14962110
[TBL] [Abstract][Full Text] [Related]
20. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales.
Flisiak I; Zaniewski P; Rogalska M; Myśliwiec H; Jaroszewicz J; Chodynicka B
Cytokine; 2010 Dec; 52(3):225-9. PubMed ID: 20980160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
